BAYER HEALTHCARE AND ORTHO-MCNEIL ANNOUNCE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT

Bayer HealthCare (BHC) and Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, announced today that they have concluded an agreement to jointly develop and market BAY 59-7939 (Factor Xa inhibitor) for the prevention and treatment of thrombosis. BAY 59-7939 is currently undergoing Phase II clinical trials. Phase III clinical trials to assess its effectiveness in the prevention of venous thromboembolism will be initiated in the next weeks.

Euronext (http://www.euronext.com/news/companypressrelease/0,4616,1700631_11894_675865428,00.html)